Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results

Ophthalmology

Volumn 110, Issue 5, 2003, Pages 979-986

  Guyer, David R ^a   Fish, Gary ^b   Haller, Julia A ^c   Ho, Allen C ^d   Klein, Michael ^e   Loewenstein, John ^f   Martin, Daniel ^g   Orth, David ^h   Rosen, Richard B ⁱ   Sanislo, Steve ^j   Schwartz, Steven D ^k   Singerman, Lawrence J ^l   Williams, George ^m  

^a OSI PHARMACEUTICALS INC   (United States)

^b TEXAS RETINA ASSOCIATES   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WILLS EYE HOSPITAL   (United States)

^e CASEY EYE INSTITUTE   (United States)

^f MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Illinois Retina Associates   (United States)

ⁱ NEW YORK EYE AND EAR INFIRMARY   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^k JULES STEIN EYE INSTITUTE   (United States)

^l Retina Associates of Cleveland   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ABRASION; ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; BLADDER; CATARACT; CHEMOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ERYTHEMA; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYELID DISEASE; EYELID EDEMA; FATIGUE; FEMALE; FOREIGN BODY; HAZE; HUMAN; INJECTION; INTRAOCULAR PRESSURE ABNORMALITY; IRIS RUBEOSIS; MALE; MEDICAL RECORD; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OCULAR PRURITUS; OPEN STUDY; OPHTHALMOLOGY; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PTOSIS; PUPIL DISEASE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RHINORRHEA; SENSATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISION; VISUAL IMPAIRMENT; VITREOUS DISEASE;

EID: 0037880734     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00085-X     Document Type: Article

References (24)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-13.
2. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987;1:330-41.
3. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1990;108:816-24.
4. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group [published erratum appears in Arch Ophthalmol 1992;110:761] Arch Ophthalmol 1991;109:1109-14.
5. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31.
6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group [published erratum appears in Arch Ophthalmol 2000;118:488]. Arch Ophthalmol 1999;117:1329-45.
7. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
8. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
9. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
11. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
13. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
14. Preclinical and Phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. The Eyetech Study Group. Retina 2002;22:143-52.
15. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-11.
16. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.
17. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar;120(3):338-46.
18. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
19. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-13.
20. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-68.
21. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.
22. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
23. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-8.
24. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). The Radiation Therapy for Age-related Macular Degeneration (RAD) Study Group. Ophthalmology 1999;106:12:2239-47.